Multi-channel ecommerce platform Shopify (NYSE: SHOP) misses third quarter 2019 earnings estimates and reported a loss for the quarter sending the stock towards the negative territory. However, revenue topped the targets. For the recently ended quarter, Shopify posted a loss of $0.29 per share compared to a profit of $0.05 per share in the third quarter of 2018.
Analysts had estimated the company to post earnings of 11 cents per share. Revenue jumped 45% to $390.6 million versus the consensus view of $383.76 million. On a GAAP basis, loss per share expanded to $0.64 from a loss of $0.22 per share in the prior-year quarter. Shopify shares were down about 5% in the pre-market trading session.
GAAP operating expenses for the three months ended September 30, 2019, increased to $252 million from $181 million in the prior year period, while non-GAAP operating expenses increased to $209 million from $154 million.
For fiscal 2019, Shopify expects revenue to be between $1.545 billion and $1.555 billion. GAAP operating loss is expected to be in the range of $158 million to $168 million.
For the fourth quarter of 2019, revenue is touted be in the range of $472 million to $482 million and GAAP operating loss is estimated to be in the range of $47 million to $57 million.
Shopify, which surpassed one million merchants in its platform during the third quarter, reported a 48% year-over-year increase in gross merchandise volume (GMV) to $14.8 billion. Gross payments volume (GPV) grew to $6.2 billion from $4.1 billion in the year-ago quarter.
As part of its expansion initiatives, Shopify completed the acquisition of warehouse fulfillment solutions provider 6 River Systems two weeks back.
SHOP stock had surged 135% so far this year and 144% from this time last year.
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings
Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key